The Numbers Are Real

For the first time in a generation, America's obesity rate is going in the right direction.

According to Gallup's National Health and Well-Being Index — a survey of 16,946 U.S. adults conducted in the first three quarters of 2025 — 37% of American adults are now classified as obese. That's down from a record high of 39.9% in 2022, as reported by both NPR and ScienceAlert.

Do the math. That's roughly 7.6 million fewer obese Americans compared to three years ago.

Separately, EPIC Research tracked millions of patient records across U.S. hospitals from Q2 2021 through Q1 2026. According to the NY Post's coverage of EPIC's data, obesity rates in that patient population dropped from 42.3% to 40.7% over the same period — a modest but statistically consistent decline.

Multiple datasets from different methodologies are pointing the same direction.

What's Driving It

GLP-1 receptor agonist drugs — semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) — are the most credible explanation.

Gallup found that 12.4% of American adults are now taking GLP-1 drugs for weight loss, up from just 5.8% in February 2024. That's more than doubled in roughly 18 months. EPIC Research's data shows GLP-1 prescriptions increased more than fourfold between 2021 and early 2026, reaching 8,819 prescriptions per 100,000 patients.

There's no randomized control trial proving causation here. But the correlation is difficult to dismiss. The age groups with the highest GLP-1 usage are showing the steepest obesity declines. According to NPR's coverage of the Gallup data, adults aged 50-64 — the heaviest users of the drugs — saw obesity drop 5 full percentage points, down to 42.8%.

The youngest and oldest Americans, who use these drugs the least, saw almost NO change.

What Mainstream Coverage Is Missing

Diabetes is at an all-time high. The same Gallup survey that showed falling obesity rates found that 13.8% of U.S. adults now report a diabetes diagnosis — the highest ever recorded. ScienceAlert flagged this directly. NPR mentioned it briefly. Most headlines didn't lead with it.

GLP-1 drugs were originally developed to treat Type 2 diabetes, not obesity. The drugs are helping people lose weight. But diabetes — a mostly lifelong condition — isn't reversing on the same timeline. Fewer obese Americans tomorrow may mean fewer new diabetes cases in the future. But that future hasn't arrived yet.

Access is still a massive problem. Only about 12% of Americans are currently on a GLP-1, according to Pew Research Center. Cost is a primary barrier. Novo Nordisk's patent on semaglutide doesn't expire until 2032. Until then, no cheap American generics. Meanwhile, according to the NY Post, countries like India, Brazil, China, and Turkey can already access generic semaglutide for as little as $15 a month. Americans are paying multiples of that — sometimes hundreds of dollars monthly — for the same molecule.

The Trump administration reportedly struck a deal with pharmaceutical companies to lower prices for some Americans, according to Pew Research Center's January 2026 analysis. The details of what that actually delivers to patients at the pharmacy counter deserve more scrutiny.

Stopping the drug reverses the gains. The NY Post noted this plainly: discontinuing GLP-1 medications leads to weight regain and increased risk of chronic conditions including Type 2 diabetes and cardiovascular disease. These aren't one-and-done cures. They're likely lifetime medications for many users. That has enormous implications for healthcare costs, insurance coverage mandates, and what happens if people lose access.

The Access Inequality

The Gallup data shows more women are using GLP-1s than men, and more middle-aged adults than younger or older ones. That demographic pattern drives which populations are seeing the most improvement.

But lower-income Americans — who have the highest obesity rates — are also the least likely to have insurance coverage for these drugs and the least able to pay out of pocket. The people who need this most are getting it least. This is a straightforward market access problem with real public health consequences.

What This Actually Means

America just recorded its first meaningful decline in obesity in decades. That's a genuine public health development.

But 37% obese is still one of the highest rates in the developed world. Diabetes is at a record high. The drug that's bending the curve costs a fortune, is patented until 2032, and stops working the moment you stop taking it.

The story isn't "Ozempic fixed obesity." The story is: a pharmaceutical intervention is doing what decades of diet advice, public health campaigns, and government programs completely failed to do — and we still haven't figured out how to get it to everyone who needs it at a price they can afford.